TY  - GEN 
AU  - Maev, I. V.
AU  - Kucheryavyy, Y. A.
AU  - Gubergrits, N. B.
AU  - Bonnacker, I.
AU  - Shelest, E. A.
AU  - Janssen-van Solingen, G. P.
AU  - Domínguez Muñoz,  Juan Enrique
PY  - 2020
SN  - 1174-5886
UR  - http://hdl.handle.net/20.500.11940/16531
AB  - BACKGROUND: Pancreatic enzyme-replacement therapy (PERT), provided as pancreatin to patients with pancreatic exocrine insufficiency (PEI), is considered an essential substitute for the pivotal physiological function the pancreas fulfills in digestion....
KW  - Lipase
KW  - Pharmaceutical Preparations
KW  - Humans
KW  - Pancreatin
KW  - Gastrointestinal Agents
KW  - Exocrine Pancreatic Insufficiency
KW  - Particle Size
TI  - Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS
DO  - 10.1007/s40268-020-00326-z
KW  - CHUS
VL  - 20
ER  -